Wenthe J

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models.

Wenthe J, Eriksson E, Hellström AC, ..., Lövgren T, Loskog A

J Transl Med 21 (1) 506 [2023-07-27; online 2023-07-27]

Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.

Irenaeus S, Hellström V, Wenthe J, ..., Loskog A, Ullenhag GJ

Cancer Gene Ther. 28 (10-11) 1188-1197 [2021-11-00; online 2020-12-14]

Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.

Wenthe J, Naseri S, Labani-Motlagh A, ..., Loskog A, Lövgren T

Cancer Immunol. Immunother. 70 (10) 2851-2865 [2021-10-00; online 2021-03-05]

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.

Wenthe J, Naseri S, Hellström AC, ..., Eriksson E, Loskog A

Cancer Gene Ther. 27 (12) 948-959 [2020-12-00; online 2020-05-01]

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.

Enblad G, Karlsson H, Gammelgård G, ..., Hagberg H, Loskog A

Clin. Cancer Res. 24 (24) 6185-6194 [2018-12-15; online 2018-08-10]